Hospital
Allina Health System
Allina Health System was paid $48.83M by Medicaid between Jan 2018 and Dec 2024, across 129 billing codes. Its largest line is 99284, emergency room visit (serious) — 37% of everything it billed.
33Billing provider infoALLINA HEALTH SYSTEM
COON RAPIDS, MN 55433
COON RAPIDS, MN 55433
33aNPI1316904287assigned 04/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.83M
24GClaims522,959
24DCodes billed129
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#3 of 36
Median peer was paid$11.46M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,641 | $4.30M | |
| 2019 | 66,315 | $7.13M | |
| 2020 | 68,029 | $6.45M | |
| 2021 | 83,284 | $7.60M | |
| 2022 | 93,377 | $8.97M | |
| 2023 | 85,677 | $8.20M | |
| 2024incomplete | 56,636 | $6.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 67,945 | 64,878 | $18.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 83,849 | 80,685 | $14.20M |
| H2035 | Alcohol and/or other drug treatment program, per hour | 7.1% | 43,464 | 5,119 | $3.47M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 4,524 | 4,102 | $1.47M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 2.9% | 4,272 | 535 | $1.41M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 11,341 | 10,632 | $933K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 15,662 | 14,172 | $905K |
| H2012 | Behavioral health day treatment, per hour | 1.8% | 6,571 | 1,225 | $886K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 35,352 | 32,792 | $761K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 27,801 | 24,996 | $720K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 8,285 | 6,713 | $641K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,311 | 1,188 | $580K |
117 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 63,049 | $530K |
| Q3014 | Telehealth originating site facility fee | <1% | 13,001 | $432K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,471 | $418K |
| 80053 | Comprehensive metabolic panel | <1% | 10,852 | $373K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,368 | $224K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,718 | $215K |
| G0378 | Hospital observation service, per hour | <1% | 931 | $199K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,714 | $195K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,911 | $178K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,821 | $163K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,285 | $158K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,129 | $146K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,390 | $137K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 609 | $105K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,777 | $91K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,810 | $87K |
| 93798 | <1% | 1,256 | $82K | |
| 90870 | <1% | 374 | $82K | |
| 99223 | Prolong inpt eval add15 m | <1% | 551 | $75K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,104 | $74K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,467 | $56K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,081 | $56K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,830 | $53K |
| 85027 | <1% | 2,732 | $44K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 355 | $44K |
| 84484 | <1% | 8,982 | $41K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 525 | $34K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 787 | $30K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 407 | $30K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,773 | $28K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 135 | $25K |
| 81001 | <1% | 3,105 | $24K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 475 | $21K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 230 | $21K |
| 82248 | <1% | 4,779 | $19K | |
| 83690 | <1% | 3,959 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,746 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 633 | $13K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 158 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 239 | $10K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 80 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 209 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 57 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,649 | $7K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 109 | $7K |
| 99220 | <1% | 59 | $7K | |
| 84703 | <1% | 985 | $7K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 112 | $6K |
| 84145 | <1% | 247 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 32 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 234 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,082 | $6K |
| 99226 | <1% | 60 | $5K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 149 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 449 | $4K |
| 99221 | <1% | 62 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 975 | $4K |
| 86140 | <1% | 745 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 82 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 197 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 519 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,044 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $4K |
| 99255 | <1% | 26 | $4K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 69 | $3K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 37 | $2K |
| 99253 | <1% | 33 | $2K | |
| 99217 | <1% | 45 | $2K | |
| 96376 | <1% | 122 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 166 | $2K |
| 83605 | <1% | 480 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 827 | $2K |
| 85610 | <1% | 680 | $2K | |
| 99254 | <1% | 15 | $2K | |
| 82565 | <1% | 214 | $1K | |
| 81003 | <1% | 290 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 82 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 702 | $1K |
| 59025 | Fetal non-stress test | <1% | 15 | $1K |
| 76820 | <1% | 17 | $1K | |
| 93016 | <1% | 66 | $1K | |
| 85379 | <1% | 88 | $937.91 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 186 | $745.61 |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $681.85 |
| 93018 | <1% | 66 | $674.48 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 788 | $649.49 |
| 93308 | <1% | 35 | $633.09 | |
| 83735 | <1% | 203 | $527.89 | |
| 93321 | <1% | 92 | $439.57 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 99 | $437.24 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 226 | $434.03 |
| 99152 | <1% | 46 | $364.02 | |
| 87081 | <1% | 61 | $341.33 | |
| 83880 | <1% | 60 | $340.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 73 | $308.15 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 242 | $272.65 |
| 81025 | <1% | 43 | $260.57 | |
| 80306 | <1% | 12 | $234.06 | |
| 99497 | <1% | 12 | $232.32 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 112 | $216.03 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 28 | $209.44 |
| 93325 | <1% | 92 | $198.32 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 31 | $189.06 |
| 87807 | <1% | 27 | $186.14 | |
| 84512 | <1% | 13 | $184.11 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $171.94 |
| 84702 | <1% | 13 | $117.88 | |
| 84132 | <1% | 98 | $97.11 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 46 | $89.55 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 28 | $67.67 |
| 82550 | <1% | 12 | $40.96 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $23.82 |
| 84295 | <1% | 26 | $19.23 | |
| A9270 | Non-covered item or service | <1% | 1,607 | $13.98 |
| C1769 | Guide wire | <1% | 15 | $1.84 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 13,463 | $0.57 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOSTREM, JILL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Allina Health System | Saint Paul, MN | $25.67M |
| Allina Health System | Saint Paul, MN | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.